Tomas Philipson

Names

Identifer

Contact

Affiliations

• University of Southern California / Leonard D. Schaeffer Center for Health Policy and Economics (weight: 50%)
  • EDIRC entry
  • location:
• National Bureau of Economic Research (NBER) (weight: 1%)
  • EDIRC entry
  • location:
• University of Chicago / Harris School of Public Policy (weight: 49%)
  • EDIRC entry
  • location:

Research profile

author of:

• Disease Eradication: Private versus Public Vaccination (RePEc:aea:aecrev:v:87:y:1997:i:1:p:222-30)
  by Geoffard, Pierre-Yves & Philipson, Tomas
• An Empirical Examination of Information Barriers to Trade in Insurance (RePEc:aea:aecrev:v:89:y:1999:i:4:p:827-846)
  by Tomas Philipson & John Cawley
• Longevity Complementarities under Competing Risks (RePEc:aea:aecrev:v:89:y:1999:i:5:p:1358-1371)
  by Tomas J. Philipson & William H. Dow & Xavier Sala-i-Martin
• The Rise in Old-Age Longevity and the Market for Long-Term Care (RePEc:aea:aecrev:v:92:y:2002:i:1:p:295-306)
  by Darius Lakdawalla & Tomas Philipson
• The Quantity and Quality of Life and the Evolution of World Inequality (RePEc:aea:aecrev:v:95:y:2005:i:1:p:277-291)
  by Gary S. Becker & Tomas J. Philipson & Rodrigo R. Soares
• Welfare-Enhancing Technological Change and the Growth of Obesity (RePEc:aea:aecrev:v:95:y:2005:i:2:p:253-257)
  by Darius Lakdawalla & Tomas Philipson & Jay Bhattacharya
• Integrated Insurance Design in the Presence of Multiple Medical Technologies (RePEc:aea:aecrev:v:97:y:2007:i:2:p:427-432)
  by Tomas J. Philipson & Dana Goldman
• Is the Obesity Epidemic a Public Health Problem? A Review of Zoltan J. Acs and Alan Lyles's Obesity, Business and Public Policy (RePEc:aea:jeclit:v:46:y:2008:i:4:p:974-82)
  by Tomas J. Philipson & Richard A. Posner
• Is the Food And Drug Administration Safe And Effective? (RePEc:aea:jecper:v:22:y:2008:i:1:p:85-102)
  by Tomas J. Philipson & Eric Sun
• Health and Wealth Disparities in the United States (RePEc:aei:rpbook:50896)
  by Tomas J. Philipson & Anupam B. Jena & Eric C. Sun
• Geographic Variation in Health Care: The Role of Private Markets (RePEc:bin:bpeajo:v:41:y:2010:i:2010-01:p:325-361)
  by Tomas J. Philipson & Seth A. Seabury & Lee M. Lockwood & Dana P. Goldman & Darius N. Lakdawalla
• `Me-Too' Innovation in Pharmaceutical Markets (RePEc:bpj:fhecpo:v:12:y:2009:i:1:n:5)
  by Jena Anupam B & Calfee John E. & Mansley Edward C & Philipson Tomas J
• The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 (RePEc:bpj:fhecpo:v:13:y:2010:i:2:n:1)
  by Sun Eric & Jena Anupam B & Lakdawalla Darius & Reyes Carolina & Philipson Tomas J & Goldman Dana
• The Option Value of Innovation (RePEc:bpj:fhecpo:v:15:y:2012:i:2:n:5)
  by Thornton Snider Julia & Romley John A. & Vogt William B. & Philipson Tomas J.
• A Reexamination of the Costs of Medical R&D Regulation (RePEc:bpj:fhecpo:v:15:y:2012:i:2:p:1-28:n:10)
  by Philipson Tomas J. & Sun Eric & Goldman Dana & Jena Anupam B.
• Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors (RePEc:bpj:fhecpo:v:16:y:2013:i:1:p:22:n:10)
  by Sood Neeraj & Philipson Tomas J. & Huckfeldt Peter
• Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&D for Neglected Diseases (RePEc:bpj:fhecpo:v:16:y:2013:i:1:p:36:n:8)
  by Jena Anupam B. & Mechoulan Stéphane & Philipson Tomas J.
• The Value of Diagnostic Testing in Personalized Medicine (RePEc:bpj:fhecpo:v:16:y:2013:i:2:p:121-133:n:6)
  by Goldman Dana P. & Lakdawalla Darius & Sood Neeraj & Gupta Charu & Vasudeva Eshan & Trakas Kostas & Riley Ralph & Agus David & Jena Anupam B. & Philipson Tomas J.
• A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies (RePEc:bpj:fhecpo:v:17:y:2014:i:1:p:32:n:5)
  by Stevens Warren & Philipson Tomas & Wu Yanyu & Chen Connie & Lakdawalla Darius
• Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital? (RePEc:bpj:fhecpo:v:17:y:2014:i:2:p:21:n:3)
  by Lakdawalla Darius N. & Snider Julia Thornton & Linthicum Mark T. & Perlroth Daniella J. & LaVallee Chris & Philipson Tomas J. & Partridge Jamie S. & Wischmeyer Paul E.
• Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection (RePEc:bpj:fhecpo:v:19:y:2016:i:1:p:141-156:n:6)
  by Seabury Seth A. & Goldman Dana P. & Lakdawalla Darius N. & Gupta Charu N. & Khan Zeba M. & Chandra Amitabh & Philipson Tomas J.
• Public Financing and the Market for Long-Term Care (RePEc:bpj:fhecpo:v:4:y:2001:n:4)
  by Lakdawalla Darius & Philipson Thomas
• Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process (RePEc:bpj:fhecpo:v:8:y:2005:n:2)
  by Berndt Ernst R. & Gottschalk Adrian H. B. & Philipson Tomas & Strobeck Matthew W.
• Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs (RePEc:bpj:fhecpo:v:biomedical_research:y:2006:n:3)
  by Philipson Tomas J & Jena Anupam B
• The Value of Life Near its End and Terminal Care (RePEc:cla:levarc:122247000000001428)
  by Gary Becker & Kevin Murphy & Tomas Philipson
• Death, Tetanus and Aerobics: The Evaluation of Disease-Specific Health Interventions (RePEc:cpr:ceprdp:1283)
  by Holmes, Jessica & Philipson, Tomas & Sala-i-Martin, Xavier & Tahvonen, Olli
• Disease Eradication: Private vs. Public Vaccination (RePEc:del:abcdef:95-09)
  by Geoffard, P.Y. & Philipson, T.
• Rational Epidemics and their Public Control (RePEc:del:abcdef:95-15)
  by Geoffard, P.Y. & Philipson, T.
• Pricing and R&D with Related Margins (RePEc:del:abcdef:98-14)
  by Geoffard, P.Y. & Philipson, T.
• Data MArkets and OPtimal Sample Size Determination (RePEc:del:abcdef:98-15)
  by Geoffard, P.Y. & Philipson, T.
• Subject Evaluation in Social Experiments (RePEc:ecm:emetrp:v:66:y:1998:i:2:p:381-408)
  by Tomas Philipson & Larry V. Hedges
• Data Markets, Missing Data, and Incentive Pay (RePEc:ecm:emetrp:v:69:y:2001:i:4:p:1099-1111)
  by Philipson, Tomas
• The evaluation of new health care technology: The labor economics of statistics (RePEc:eee:econom:v:76:y:1997:i:1-2:p:375-395)
  by Philipson, Tomas
• Measurement errors: A principal investigator-agent approach (RePEc:eee:econom:v:91:y:1999:i:2:p:273-298)
  by Philipson, Tomas & Malani, Anup
• Multiple-output agency incentives in data production: experimental evidence (RePEc:eee:eecrev:v:41:y:1997:i:3-5:p:961-970)
  by Philipson, Tomas & Lawless, Thomas
• The growth of obesity and technological change (RePEc:eee:ehbiol:v:7:y:2009:i:3:p:283-293)
  by Lakdawalla, Darius & Philipson, Tomas
• Economic epidemiology and infectious diseases (RePEc:eee:heachp:1-33)
  by Philipson, Tomas
• Social Welfare and Measurement of Segregation (RePEc:eee:jetheo:v:60:y:1993:i:2:p:322-334)
  by Philipson Tomas
• The welfare loss of disease and the theory of taxation (RePEc:eee:jhecon:v:14:y:1995:i:3:p:387-395)
  by Philipson, Tomas
• An empirical examination of the implications of assortative matching on the incidence of HIV (RePEc:eee:jhecon:v:15:y:1996:i:6:p:735-749)
  by Dow, William H. & Philipson, Tomas
• Cost-effectiveness analysis and innovation (RePEc:eee:jhecon:v:27:y:2008:i:5:p:1224-1236)
  by Jena, Anupam B. & Philipson, Tomas J.
• An economic evaluation of the war on cancer (RePEc:eee:jhecon:v:29:y:2010:i:3:p:333-346)
  by Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J.
• The impact of comparative effectiveness research on health and health care spending (RePEc:eee:jhecon:v:30:y:2011:i:4:p:695-706)
  by Basu, Anirban & Jena, Anupam B. & Philipson, Tomas J.
• Endogenous cost-effectiveness analysis and health care technology adoption (RePEc:eee:jhecon:v:32:y:2013:i:1:p:172-180)
  by Jena, Anupam B. & Philipson, Tomas J.
• The nonprofit sector and industry performance (RePEc:eee:pubeco:v:90:y:2006:i:8-9:p:1681-1698)
  by Lakdawalla, Darius & Philipson, Tomas
• Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts (RePEc:eee:pubeco:v:92:y:2008:i:5-6:p:1306-1325)
  by Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric
• Economics of Obesity (RePEc:elg:eechap:14021_7)
  by Peter J. Huckfeldt & Darius N. Lakdawalla & Tomas J. Philipson
• A direct test of the 'lemons' model: the market for used pickup trucks (RePEc:elg:eechap:2759_13)
  by John Cawley & Tomas Philipson
• Economics of Obesity (RePEc:elg:eechap:3572_7)
  by Darius Lakdawalla & Tomas J. Philipson
• Unknown item RePEc:fth:chices:129 (paper)
• Unknown item RePEc:fth:chices:132 (paper)
• Unknown item RePEc:fth:chices:134 (paper)
• Unknown item RePEc:fth:chices:146 (paper)
• Merit Motives and Government Intervention: Public Finance in Reverse (RePEc:fth:chiprc:2000-03)
  by Casey Mulligan & Tomas Philipson
• Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS (RePEc:fth:chiprc:93-3)
  by Avner Ahituv & V. Joseph Hotz & Tomas Philipson
• Estimating the Extent of Trade Under Incomplete Information: The Case of HIV (RePEc:fth:chiprc:94-8)
  by Tomas Philipson & Edward Vytlacil
• Self-Interested Treatment Evaluation in Experiments (RePEc:fth:chiprc:95-1)
  by Tomas J. Philipson
• Is Health Care Technology Over-Approved? A Meta-Analysis of Revealed Preference (RePEc:fth:chiprc:95-8)
  by Larry V. Hedges & Tomas Philipson
• Nonprofit Production (RePEc:fth:chiprc:97-8)
  by Tomas Philipson & Darius Lakdawalla
• The Private Demand for Information and the Effects of Public Testing Programs: The Case of HIV (RePEc:fth:yalegr:750)
  by Boozer, M. & Philipson, T.
• External Costs of Risky Health Behaviors Associated with Leading Actual Causes of Death in the U.S.: A Review of the Evidence and Implications for Future Research (RePEc:gam:jijerp:v:7:y:2010:i:6:p:2460-2472:d:8551)
  by Armineh Zohrabian & Tomas J Philipson
• The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination (RePEc:har:wpaper:0203)
  by Darius Lakdawalla & Tomas Philipson
• The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US (RePEc:har:wpaper:0209)
  by Frank R. Lichtenberg & Tomas J. Philipson
• Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS (RePEc:har:wpaper:9401)
  by Avner Ahituv & V. Joseph Hotz & Tomas Philipson
• Aging and the Growth of Long-Term Care (RePEc:har:wpaper:9909)
  by Darius Lakdawalla & Tomas Philipson
• The Long-Run Growth in Obesity as a Function of Technological Change (RePEc:har:wpaper:9912)
  by Tomas J. Philipson & Richard A. Posner
• External Treatment Effects and Program Implementation Bias (RePEc:har:wpaper:9929)
  by Tomas Philipson
• Rational Epidemics and Their Public Control (RePEc:ier:iecrev:v:37:y:1996:i:3:p:603-24)
  by Geoffard, Pierre-Yves & Philipson, Tomas
• Dynamic information release (RePEc:kap:jeczfn:v:53:y:1991:i:2:p:205-213)
  by Tomas Philipson
• Equilibrium and Efficiency in an Organized Vote Market (RePEc:kap:pubcho:v:89:y:1996:i:3-4:p:245-65)
  by Philipson, Tomas J & Snyder, James M, Jr
• The Effects of Product Liability Exemption in the Presence of the FDA (RePEc:nbr:nberch:11962)
  by Tomas J. Philipson & Eric Sun & Dana Goldman
• "Me-Too" Innovation in Pharmaceutical Markets (RePEc:nbr:nberch:12340)
  by Anupam B. Jena & John E. Calfee & Edward C. Mansley & Tomas J. Philipson
• The Economic Value and Pricing of Personalized Medicine (RePEc:nbr:nberch:13997)
  by Tomas J. Philipson
• Asymmetric Information and the Not-for-Profit Sector Does Its Output Sell a a Premium? (RePEc:nbr:nberch:6770)
  by Tomas Philipson
• Medical Care Output and Productivity in the Nonprofit Sector (RePEc:nbr:nberch:7627)
  by Tomas Philipson & Darius Lakdawalla
• Public Financing and the Market for Long-Term Care (RePEc:nbr:nberch:9852)
  by Darius Lakdawalla & Tomas Philipson
• Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process (RePEc:nbr:nberch:9874)
  by Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck
• Theories of Firm Behavior in the Nonprofit Sector. A Synthesis and Empirical Evaluation (RePEc:nbr:nberch:9970)
  by Anup Malani & Tomas Philipson & Guy David
• Observational Agency and Supply-Side Econometrics (RePEc:nbr:nberte:0210)
  by Tomas Philipson
• External Treatment Effects and Program Implementation Bias (RePEc:nbr:nberte:0250)
  by Tomas J. Philipson
• Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process (RePEc:nbr:nberwo:10822)
  by Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck
• Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts (RePEc:nbr:nberwo:11724)
  by Tomas J. Philipson & Ernst R. Berndt & Adrian H. B. Gottschalk & Matthew W. Strobeck
• Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs (RePEc:nbr:nberwo:11810)
  by Tomas J. Philipson & Anupam B. Jena
• Health Care, Technological Change, and Altruistic Consumption Externalities (RePEc:nbr:nberwo:11930)
  by Tomas Philipson & Stephane Mechoulan & Anupam Jena
• Surplus Appropriation from R&D and Health Care Technology Assessment Procedures (RePEc:nbr:nberwo:12016)
  by Tomas J. Philipson & Anupam B. Jena
• Antitrust in the Not-For-Profit Sector (RePEc:nbr:nberwo:12132)
  by Tomas J. Philipson & Richard A. Posner
• Intellectual Property and Marketing (RePEc:nbr:nberwo:12577)
  by Darius Lakdawalla & Tomas Philipson & Y. Richard Wang
• Integrated Insurance Design in the Presence of Multiple Medical Technologies (RePEc:nbr:nberwo:12870)
  by Dana Goldman & Tomas Philipson
• The Value of Life Near its End and Terminal Care (RePEc:nbr:nberwo:13333)
  by Gary Becker & Kevin Murphy & Tomas Philipson
• Is the Food and Drug Administration Safe and Effective? (RePEc:nbr:nberwo:13561)
  by Tomas J. Philipson & Eric Sun
• Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity (RePEc:nbr:nberwo:14010)
  by Tomas Philipson & Richard Posner
• The Value of Life in General Equilibrium (RePEc:nbr:nberwo:14157)
  by Anupam Jena & Casey Mulligan & Tomas J. Philipson & Eric Sun
• Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption (RePEc:nbr:nberwo:15032)
  by Anupam Jena & Tomas Philipson
• An Economic Evaluation of the War on Cancer (RePEc:nbr:nberwo:15574)
  by Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman
• The Effects of Product Liability Exemption in the Presence of the FDA (RePEc:nbr:nberwo:15603)
  by Tomas J. Philipson & Eric C. Sun & Dana Goldman
• The Impact of Comparative Effectiveness Research on Health and Health Care Spending (RePEc:nbr:nberwo:15633)
  by Anirban Basu & Tomas J. Philipson
• Terminal Care and The Value of Life Near Its End (RePEc:nbr:nberwo:15649)
  by Tomas J. Philipson & Gary Becker & Dana Goldman & Kevin M. Murphy
• Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets (RePEc:nbr:nberwo:17011)
  by Anup Malani & Tomas J. Philipson
• Public Liabilities and Health Care Policy (RePEc:nbr:nberwo:18571)
  by Kristopher J. Hult & Tomas J. Philipson
• Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension (RePEc:nbr:nberwo:19005)
  by Tomas J. Philipson & George Zanjani
• Adjusting National Accounting for Health: Is the Business Cycle Countercyclical? (RePEc:nbr:nberwo:19058)
  by Mark L. Egan & Casey B. Mulligan & Tomas J. Philipson
• International Health Economics (RePEc:nbr:nberwo:19280)
  by Mark Egan & Tomas J. Philipson
• Financial Health Economics (RePEc:nbr:nberwo:20075)
  by Ralph Koijen & Tomas Philipson & Harald Uhlig
• Health Care Adherence and Personalized Medicine (RePEc:nbr:nberwo:20330)
  by Mark Egan & Tomas J. Philipson
• How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations (RePEc:nbr:nberwo:22986)
  by Kristopher J. Hult & Sonia Jaffe & Tomas J. Philipson
• Sharing R&D Risk in Healthcare via FDA Hedges (RePEc:nbr:nberwo:23344)
  by Adam Jørring & Andrew W. Lo & Tomas J. Philipson & Manita Singh & Richard T. Thakor
• Disease Complementarities and the Evaluation of Public Health Interventions (RePEc:nbr:nberwo:5216)
  by William H. Dow & Jessica Holmes & Tomas Philipson & Xavier Sala-i-Martin
• An Empirical Examination of Information Barriers to Trade in Insurance (RePEc:nbr:nberwo:5669)
  by John Cawley & Tomas Philipson
• Mortality Contingent Claims, Health Care, and Social Insurance (RePEc:nbr:nberwo:5760)
  by Tomas Philipson & Gary S. Becker
• The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims (RePEc:nbr:nberwo:6042)
  by Charles Mullin & Tomas Philipson
• Consumption vs. Production of Insurance (RePEc:nbr:nberwo:6225)
  by Tomas Philipson & George Zanjani
• Nonprofit Production and Competition (RePEc:nbr:nberwo:6377)
  by Darius Lakdawalla & Tomas Philipson
• The Rise in Old Age Longevity and the Market for Long-Term Care (RePEc:nbr:nberwo:6547)
  by Darius Lakdawalla & Tomas Philipson
• Aging and the Growth of Long-Term Care (RePEc:nbr:nberwo:6980)
  by Darius Lakdawalla & Tomas Philipson
• Economic Epidemiology and Infectious Diseases (RePEc:nbr:nberwo:7037)
  by Tomas Philipson
• The Long-Run Growth in Obesity as a Function of Technological Change (RePEc:nbr:nberwo:7423)
  by Tomas J. Philipson & Richard A. Posner
• Merit Motives and Government Intervention: Public Finance in Reverse (RePEc:nbr:nberwo:7698)
  by Casey B. Mulligan & Tomas J. Philipson
• Antitrust and the Not-For-Profit Sector (RePEc:nbr:nberwo:8126)
  by Tomas J. Philipson & Richard A. Posner
• The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination (RePEc:nbr:nberwo:8946)
  by Darius Lakdawalla & Tomas Philipson
• The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry (RePEc:nbr:nberwo:9303)
  by Frank R. Lichtenberg & Tomas J. Philipson
• Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets (RePEc:nbr:nberwo:9598)
  by Tomas Philipson & Stephane Mechoulan
• The Quantity and Quality of Life and the Evolution of World Inequality (RePEc:nbr:nberwo:9765)
  by Gary S. Becker & Tomas J. Philipson & Rodrigo R. Soares
• A Theoretical and Empirical Investigation of the Effects of Public Health Subsidies for STD Testing (RePEc:oup:qjecon:v:110:y:1995:i:2:p:445-474.)
  by Tomas J. Philipson & Richard A. Posner
• Sharing R&D Risk in Healthcare via FDA Hedges
  [Bank lines of credit as contingent liquidity: Covenant violations and their implications] (RePEc:oup:rcorpf:v:11:y:2022:i:4:p:880-922.)
  by Adam Jørring & Andrew W Lo & Tomas J Philipson & Manita Singh & Richard T Thakor
• Data Markets and the Production of Surveys (RePEc:oup:restud:v:64:y:1997:i:1:p:47-72.)
  by Tomas Philipson
• Pricing and R&D When Consumption Affects Longevity (RePEc:rje:randje:v:33:y:2002:i:spring:p:85-95)
  by Pierre-Yves Geoffard & Tomas Philipson
• Desegregation and Social Monopoly Pricing (RePEc:sae:ratsoc:v:4:y:1992:i:2:p:189-198)
  by Tomas Philipson
• Evaluating an Argument for Affirmative Action (RePEc:sae:ratsoc:v:4:y:1992:i:3:p:360-364)
  by James J. Heckman & Thomas J. Philipson
• `Rational Choice, Public Policy And Aids' (RePEc:sae:ratsoc:v:8:y:1996:i:4:p:498-502)
  by Tomas J. Philipson & Richard A. Posner
• Defining Value: The Need for a Longer, Broader View (RePEc:spr:pharme:v:35:y:2017:i:7:d:10.1007_s40273-017-0503-7)
  by Tomas J. Philipson & Sachin Kamal-Bahl & Anupam B. Jena
• How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations (RePEc:tpr:amjhec:v:4:y:2018:i:4:p:433-453)
  by Kristopher J. Hult & Sonia Jaffe & Tomas J. Philipson
• How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations (RePEc:ucp:amjhec:v:4:y:2018:i:4:p:433-453)
  by Kristopher J. Hult & Sonia Jaffe & Tomas J. Philipson
• Labor Markets in Statistics: The Subject Supply Effect in Medical R&D (RePEc:ucp:jhucap:doi:10.1086/702923)
  by Anup Malani & Tomas J. Philipson
• The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry (RePEc:ucp:jlawec:doi:10.1086/374703)
  by Frank R. Lichtenberg & Tomas J. Philipson
• The Regulation of Medical Innovation and Pharmaceutical Markets (RePEc:ucp:jlawec:doi:10.1086/376586)
  by Tomas J. Philipson
• Altruism and Innovation in Health Care (RePEc:ucp:jlawec:doi:10.1086/648383)
  by Anupam B. Jena & Stéphane Mechoulan & Tomas J. Philipson
• Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets (RePEc:ucp:jlawec:doi:10.1086/663345)
  by Darius Lakdawalla & Tomas Philipson
• Public Spending on AIDS Education: An Economic Analysis (RePEc:ucp:jlawec:v:37:y:1994:i:1:p:17-38)
  by Philipson, Tomas & Posner, Richard A
• The Economic Epidemiology of Crime (RePEc:ucp:jlawec:v:39:y:1996:i:2:p:405-33)
  by Philipson, Tomas J & Posner, Richard A
• Antitrust in the Not-for-Profit Sector (RePEc:ucp:jlawec:v:52:y:2009:i:1:p:1-18)
  by Tomas J. Philipson & Richard A. Posner
• Managed Care and the Quality of Health Care: A Misguided Debate? (RePEc:ucp:jlstud:v:30:y:2001:i:2:p:753-58)
  by Philipson, Thomas
• Old-Age Longevity and Mortality-Contingent Claims (RePEc:ucp:jpolec:v:106:y:1998:i:3:p:551-573)
  by Tomas J. Philipson & Gary S. Becker
• Death, tetanus, and aerobics: The evaluation of disease-specific health interventions (RePEc:upf:upfgen:124)
  by William H. Dow & Jessica Holmes & Tomas Philipson & Xavier Sala-i-Martin
• Health investment complementarities under competing risks (RePEc:upf:upfgen:192)
  by William H. Dow & Tomas Philipson & Xavier Sala-i-Martin & Jessica Holmes
• Private Vaccination and Public Health: An Empirical Examination for U.S. Measles (RePEc:uwp:jhriss:v:31:y:1996:i:3:p:611-630)
  by Tomas Philipson
• The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS (RePEc:uwp:jhriss:v:31:y:1996:i:4:p:869-897)
  by Avner Ahituv & V. Joseph Hotz & Tomas Philipson
• The Impact of Public Testing for Human Immunodeficiency Virus (RePEc:uwp:jhriss:v:35:y:2000:i:3:p:419-446)
  by Michael A. Boozer & Tomas J. Philipson
• Labor Supply and Weight (RePEc:uwp:jhriss:v:42:y:2007:i1:p85-116)
  by Darius Lakdawalla & Tomas Philipson
• Financial Health Economics (RePEc:wly:emetrp:v:84:y:2016:i::p:195-242)
  by Ralph S. J. Koijen & Tomas J. Philipson & Harald Uhlig
• The world‐wide growth in obesity: an economic research agenda (RePEc:wly:hlthec:v:10:y:2001:i:1:p:1-7)
  by Tomas Philipson
• The institute of medicine report on the FDA: where is the science? (RePEc:wly:hlthec:v:16:y:2007:i:3:p:219-221)
  by Tomas Philipson & Anupam B. Jena & Eric Sun
• Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA (RePEc:wly:hlthec:v:19:y:2010:i:10:p:1109-1116)
  by Dana Goldman & Darius Lakdawalla & Tomas J. Philipson & Wesley Yin
• Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA (RePEc:wly:hlthec:v:19:y:2010:i:12:p:1510-1510)
  by Dana Goldman & Darius Lakdawalla & Tomas J. Philipson & Wesley Yin
• Heterogeneity In Action: The Role Of Passive Personalization In Comparative Effectiveness Research (RePEc:wly:hlthec:v:23:y:2014:i:3:p:359-373)
  by Anirban Basu & Anupam B. Jena & Dana P. Goldman & Tomas J. Philipson & Robert Dubois
• Response To Epstein'S Comment On “Heterogeneity In Action” (RePEc:wly:hlthec:v:23:y:2014:i:3:p:376-378)
  by Anirban Basu & Anupam B. Jena & Dana P. Goldman & Tomas J. Philipson & Robert Dubois
• Commentary (RePEc:wly:mgtdec:v:28:y:2007:i:4-5:p:437-438)
  by Tomas J. Philipson
• Commentary (RePEc:wly:mgtdec:v:28:y:2007:i:4-5:p:453-454)
  by Tomas J. Philipson
• Commentary (RePEc:wly:mgtdec:v:28:y:2007:i:4-5:p:467-468)
  by Tomas J. Philipson
• Surplus Appropriation from R&D and Health Care Technology Assessment Procedures (RePEc:wpa:wuwppe:0511021)
  by Tomas J. Philipson & Anupam B. Jena
• Mortality Contingent Claims, Health Care, and Social Insurance (RePEc:zbw:cbscwp:129)
  by Philipson, Tomas J. & Becker, Gary S.
• An Empirical Examination of Information Barriers to Trade in Insurance (RePEc:zbw:cbscwp:132)
  by Cawley, John & Philipson, Tomas J.
• The Future of Old-Age Longevity: Competitive Pricing of Morality Contingent Claims (RePEc:zbw:cbscwp:134)
  by Mullin, Charles & Philipson, Tomas J.
• The Rise in Old Age Longevity and the Market for Long-Term Care (RePEc:zbw:cbscwp:146)
  by Philipson, Tomas J. & Lakdawalla, Darius
• Merit Motives & Government Intervention: Public Finance in Reverse (RePEc:zbw:cbscwp:159)
  by Mulligan, Casey B. & Philipson, Tomas J.
• The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination (RePEc:zbw:cbscwp:174)
  by Lakdawalla, Darius & Philipson, Tomas J.
• The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in The US Pharmaceuticals Industry (RePEc:zbw:cbscwp:178)
  by Lichtenberg, Frank R. & Philipson, Tomas J.
• Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets (RePEc:zbw:cbscwp:198)
  by Philipson, Tomas J. & Mechoulan, Stéphane
• Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts (RePEc:zbw:cbscwp:199)
  by Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Strobeck, Matthew W.
• Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets (RePEc:zbw:cbscwp:204)
  by Philipson, Tomas J. & Jena, Anupam B. & Mechoulan, Stéphane
• Intellectual Property and Marketing (RePEc:zbw:cbscwp:216)
  by Philipson, Tomas J. & Lakdawalla, Darius
• Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts (RePEc:zbw:cbscwp:217)
  by Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric
• Is the Food and Drug Administration Safe and Effective? (RePEc:zbw:cbscwp:218)
  by Philipson, Tomas J. & Sun, Eric
• Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets (RePEc:zbw:cbscwp:237)
  by Malani, Anup & Philipson, Tomas J.
• Adjusting Measures of Economic Output for Health: Is the Business Cycle Countercyclical? (RePEc:zbw:cbscwp:246)
  by Egan, Mark L. & Mulligan, Casey B. & Philipson, Tomas J.
• International Health Economics (RePEc:zbw:cbscwp:251)
  by Egan, Mark L. & Philipson, Tomas J.